CytoMed Therapeutics Limited Rings the Closing Bell in Celebration of its IPO
About This Event
CytoMed Therapeutics Limited (Nasdaq: GDTC), a biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel allogeneic cell-based immunotherapies for the treatment of human cancers, visits the Nasdaq MarketSite in Times Square. In honor of the occasion, Peter Choo Chee Kong, Chairman, rings the Closing Bell.